0001795251 false Q2 --12-31 2026-06-30 0001795251 2026-01-01 2026-06-30 0001795251 us-gaap:SubsequentEventMember 2026-08-31 2026-08-31 0001795251 2026-08-13 2026-08-13 0001795251 us-gaap:SubsequentEventMember 2026-08-13 2026-08-13 0001795251 us-gaap:SubsequentEventMember srt:MaximumMember 2026-08-07 2026-08-07 0001795251 us-gaap:SubsequentEventMember srt:MinimumMember 2026-08-07 2026-08-07 0001795251 us-gaap:SubsequentEventMember 2026-08-07 2026-08-07 0001795251 us-gaap:SubsequentEventMember us-gaap:RestrictedStockUnitsRSUMember 2026-08-07 2026-08-07 0001795251 us-gaap:SubsequentEventMember 2026-08-07 0001795251 2026-07-31 2026-07-31 0001795251 us-gaap:SubsequentEventMember 2026-07-31 2026-07-31 0001795251 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001795251 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001795251 2025-01-01 2025-06-30 0001795251 2025-06-30 0001795251 2026-06-30 0001795251 2025-04-01 2025-06-30 0001795251 nnox:AIAndSoftwareSolutionsMember 2025-04-01 2025-06-30 0001795251 nnox:RadiologyServicesMember 2025-04-01 2025-06-30 0001795251 nnox:NanoxARCMember 2025-04-01 2025-06-30 0001795251 nnox:NanoxHealthITIncMember 2026-04-01 2026-06-30 0001795251 2026-04-01 2026-06-30 0001795251 nnox:AIAndSoftwareSolutionsMember 2026-04-01 2026-06-30 0001795251 nnox:RadiologyServicesMember 2026-04-01 2026-06-30 0001795251 nnox:NanoxARCMember 2026-04-01 2026-06-30 0001795251 nnox:RadiologyServicesMember 2025-01-01 2025-06-30 0001795251 nnox:NanoxARCMember 2025-01-01 2025-06-30 0001795251 nnox:AIAndSoftwareSolutionsMember 2025-06-30 0001795251 nnox:RadiologyServicesMember 2025-06-30 0001795251 nnox:NanoxARCMember 2025-06-30 0001795251 nnox:AIAndSoftwareSolutionsMember 2025-01-01 2025-06-30 0001795251 nnox:NanoxHealthITIncMember 2026-01-01 2026-06-30 0001795251 nnox:NanoxARCMember 2026-01-01 2026-06-30 0001795251 nnox:AIAndSoftwareSolutionsMember 2026-06-30 0001795251 nnox:RadiologyServicesMember 2026-06-30 0001795251 nnox:NanoxARCMember 2026-06-30 0001795251 nnox:AIAndSoftwareSolutionsMember 2026-01-01 2026-06-30 0001795251 nnox:RadiologyServicesMember 2026-01-01 2026-06-30 0001795251 nnox:FirstAnniversaryMember 2026-06-23 2026-06-23 0001795251 us-gaap:RestrictedStockUnitsRSUMember 2026-06-23 2026-06-23 0001795251 nnox:FirstAnniversaryMember 2026-01-01 2026-06-30 0001795251 us-gaap:RestrictedStockUnitsRSUMember 2026-02-05 2026-02-05 0001795251 nnox:SecondAnniversaryMember 2026-02-05 2026-02-05 0001795251 nnox:FirstAnniversaryMember 2026-02-05 2026-02-05 0001795251 2026-02-05 2026-02-05 0001795251 2025-12-31 0001795251 us-gaap:CommonStockMember 2026-05-01 2026-05-01 0001795251 nnox:MDWEBLLCMember 2025-05-01 2025-05-31 0001795251 us-gaap:CommonStockMember 2025-12-31 0001795251 us-gaap:CommonStockMember 2026-06-30 0001795251 nnox:NanoxAIMember 2026-01-01 2026-06-30 0001795251 nnox:IIAGrantsMember 2026-01-01 2026-06-30 0001795251 2023-05-01 2023-05-01 0001795251 2023-05-01 0001795251 nnox:ImageBigDataMember 2026-01-01 2026-06-30 0001795251 us-gaap:TechnologyBasedIntangibleAssetsMember 2026-01-01 2026-06-30 0001795251 nnox:AISolutionsReportingUnitMember 2026-01-01 2026-06-30 0001795251 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001795251 us-gaap:FairValueInputsLevel3Member 2026-06-30 0001795251 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-06-30 0001795251 us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-12-31 0001795251 us-gaap:CashAndCashEquivalentsMember 2025-12-31 0001795251 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001795251 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001795251 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001795251 us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001795251 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001795251 us-gaap:CommonStockMember 2026-06-30 0001795251 2024-12-31 0001795251 us-gaap:RetainedEarningsMember 2025-06-30 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001795251 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001795251 us-gaap:CommonStockMember 2025-06-30 0001795251 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001795251 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001795251 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001795251 2025-03-31 0001795251 us-gaap:RetainedEarningsMember 2025-03-31 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001795251 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001795251 us-gaap:CommonStockMember 2025-03-31 0001795251 us-gaap:RetainedEarningsMember 2026-06-30 0001795251 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001795251 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001795251 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001795251 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001795251 2026-03-31 0001795251 us-gaap:RetainedEarningsMember 2026-03-31 0001795251 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001795251 us-gaap:CommonStockMember 2026-03-31 0001795251 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-06-30 0001795251 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001795251 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001795251 us-gaap:RetainedEarningsMember 2024-12-31 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001795251 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001795251 us-gaap:CommonStockMember 2024-12-31 0001795251 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001795251 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001795251 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001795251 us-gaap:RetainedEarningsMember 2025-12-31 0001795251 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-06-30 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001795251 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0001795251 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001795251 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001795251 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001795251 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares iso4217:ILS xbrli:shares

 

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2026

 

Commission File Number: 001-39461

 

NANO-X IMAGING LTD

Ofer Tech Park

94 Shlomo Shmeltzer Road

Petach Tikva

Israel 4970602

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F           Form 40-F

 

 

 

 

CONTENTS

 

Quarterly Results of Operations 

 

On September 9, 2026, NANO-X IMAGING LTD (the “Company”, “Nanox”, “we” or “us”) announced its financial results for the second quarter ended June 30, 2026. A copy of our press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) and is incorporated herein by reference.

 

Attached hereto as Exhibit 99.2 are the unaudited, condensed consolidated financial statements of Nanox as of, and for the three and six months ended, June 30, 2026 (including the notes thereto) (the “Q2 2026 Financial Statements”).

 

Attached hereto as Exhibit 99.3 are Nanox’s Operating and Financial Review and Prospects as of, and for the six months ended, June 30, 2026.

 

Attached hereto as Exhibit 101 are the Q2 2026 Financial Statements, formatted in IXBRL (eXtensible Business Reporting Language), consisting of the sub-exhibits listed in the exhibit table below.

  

Exhibit
Number
  Document Description
99.1   Earnings press release of Nanox for the second quarter ended June 30, 2026
99.2   Unaudited, condensed consolidated financial statements of Nanox as of, and for the three and six months ended, June 30, 2026
99.3   Nanox’s review of its results of operations and financial condition as of, and for the six months ended, June 30, 2026
EX-101.INS   IXBRL Taxonomy Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
EX-101.SCH   IXBRL Taxonomy Extension Schema Document
EX-101.CAL   IXBRL Taxonomy Calculation Linkbase Document
EX-101.DEF   IXBRL Taxonomy Extension Definition Linkbase Document
EX-101.LAB   IXBRL Taxonomy Label Linkbase Document
EX-101.PRE   IXBRL Taxonomy Presentation Linkbase Document
EX-104   Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

Incorporation by Reference

 

The Q2 2026 Financial Statements attached to this Form 6-K as Exhibit 99.2 and the Operating and Financial Review and Prospects as of, and for the six months ended, June 30, 2026 attached to this Form 6-K as Exhibit 99.3, are incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-294302), and Form S-8 (File No. 333-248322).

  

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   

NANO-X IMAGING LTD    
(Registrant)    
     
Date: September 9, 2026 By: /s/ Erez Meltzer
Name: Erez Meltzer
Title: Chief Executive Officer and Acting Chairman of the Board

2


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EARNINGS PRESS RELEASE OF NANOX FOR THE SECOND QUARTER ENDED JUNE 30, 2026

UNAUDITED, CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF NANOX AS OF, AND FOR THE THREE AND SIX MONTHS ENDED, JUNE 30, 2026

NANOX'S REVIEW OF ITS RESULTS OF OPERATIONS AND FINANCIAL CONDITION AS OF, AND FOR THE SIX MONTHS ENDED, JUNE 30, 2026

XBRL SCHEMA FILE

XBRL CALCULATION FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: ea0304826-6k_nanox_htm.xml